Project Grant R03HG014803
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $418,750 Project Grant from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective April 1, 2026 through March 31, 2028. The award funds the development of a cis-regulatory element (cRE)-centric infrastructure in AnVIL (Analysis Visualization Laboratory), a cloud-based platform designed to improve understanding of how noncoding genetic...
- Federal Grant Award Summary The National Human Genome Research Institute (NHGRI) awarded Geisinger Clinic a $754,561 Project Grant under the Human Genome Research program (CFDA 93.172) effective August 14, 2025, through June 30, 2029. The project, titled "Advancing Perinatal Genomic Discoveries Through Patient Engagement and Data Sharing," develops clinical informatics tools and patient engagement mechanisms to improve diagnostic yields and precision medicine applications for...
- Federal Project Grant Award Summary Boston Children's Hospital received a $130,680 Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective July 1, 2025 through June 30, 2027. The award supports the development of computational technologies and statistical methods for single-cell functional genomics analysis. The research deliverables include: (1) deep learning computational frameworks to decode epigenetic...
- Federal Project Grant Award Summary The National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $501,618 beginning September 1, 2025, and concluding June 30, 2029. This award supports the development of computational tools for variant calling from long genomic and RNA-sequencing (RNA-seq) reads, addressing critical gaps in current genomic analysis methodologies. The project will deliver...
- Federal Grant Award Summary The National Human Genome Research Institute (NHGRI) awarded Fred Hutchinson Cancer Center a $2.409 million Project Grant (CFDA 93.172: Human Genome Research) on September 19, 2025, to develop an experimental-data-based in-silico data generation platform for improving single-cell and spatial omics analysis. The project, extending through August 31, 2029, will deliver three primary products: (1) statistical methods and tools for generating in-silico negative controls...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $863,248 Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) for a four-year project spanning February 1, 2026 through January 31, 2030. The research initiative, led by Dr. Blobel at CHOP in collaboration with Dr. Hansen at Massachusetts Institute of Technology, investigates three-dimensional (3D) chromatin architectural...
- Federal Project Grant Award Summary The National Institute of Child Health and Human Development (NICHD) awarded $434,500 to the Research Institute at Nationwide Children's Hospital under the Child Health and Human Development Extramural Research program (CFDA 93.865) for the period August 1, 2025, through July 31, 2027. The funded project, "NEOGX-III: Interpretable Machine Learning with Integrated Analysis of Maternal & Infant Electronic Medical Records for Unbiased Prediction of...
- Federal Grant Award Summary The National Human Genome Research Institute (NHGRI) awarded a $2.8 million Project Grant to The Washington University (Office of Sponsored Research Services) effective September 1, 2025, through August 31, 2029, under the Human Genome Research program (CFDA 93.172). This award supports the development and implementation of a high-throughput, genome-integrated reporter gene system designed to systematically measure enhancer activities at multiple fixed distances...
- Federal Project Grant Award Summary The Broad Institute of MIT and Harvard received a $6.7 million Project Grant from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), awarded September 8, 2025, with a completion date of June 30, 2029. This award supports the continued development and enhancement of SEQR, a freely available, open-source genomic analysis platform designed to advance rare disease discovery. The project addresses the...
- Federal Grant Award Summary The National Human Genome Research Institute (NHGRI) awarded UCLA a $780,113 Project Grant effective September 1, 2025, through August 31, 2029, under the Human Genome Research program (CFDA 93.172). This award supports the development of advanced methodological tools and theoretical frameworks to address critical limitations in current genetic association studies. The project will deliver a comprehensive simulation framework capable of efficiently modeling...
Federal Grant Award Summary The Research Institute at Nationwide Children's Hospital received a $407,000 Project Grant from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective May 1, 2026 through April 30, 2028. This award supports the development of computational methods and workflows to enhance the reuse and interoperability of genomic cohort data maintained within the NHGRI's Analysis Visualization and Informatics Lab-space (AnVIL) platform. The project specifically addresses the integration of heterogeneous genomic datasets from the Genome Research and Outcomes in Variable Populations (GREGOR) and Clinical Sequencing Evidence-Generating Research (CSER) consortia to facilitate standardized multi-cohort analyses for rare and undiagnosed disease research. The deliverables encompass two primary research objectives: (1) enhanced workflows for multi-cohort data integration through development of a plugin-based architecture that standardizes variant representation, cohort allele frequency generation, and phenotype-informed synthetic cohort creation across diverse datasets; and (2) evaluation and validation of synthetic multi-dataset cohorts for rare genetic disease research, including implementation of duplicate sample detection methodologies, dataset matching strategies, and American College of Medical Genetics (ACMG) variant pathogenicity assessment protocols. These tools and best practices will enable researchers to efficiently leverage AnVIL genomic resources for reproducible and scalable rare disease research applications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $407.0k | 5/1/26 |